FDA Revision Puts Eli Lilly Stock in Spotlight

A shift in the options pits may create additional tailwinds for LLY

Digital Content Manager
Sep 17, 2021 at 10:31 AM
facebook twitter linkedin


Drug maker Eli Lilly And Co (NYSE:LLY) is making headlines this morning, after the U.S. Food and Drug Administration (FDA) revised an emergency use authorization for the antibody cocktail the company has developed with AbCellera (ABCL) to treat Covid-19 cases. The amendment allows the combination therapy to be used on patients who are at high risk for progression to severe disease, or as a post-exposure prevention method for those who are not yet fully vaccinated.

The U.S. government has already jumped on the treatment, with Eli Lilly expected to supply 388,000 doses of its antibody drug, of which 200,000 will be delivered by the third quarter. Though the new deal could generate $330 million in revenue, LLY was last seen down 1% at $228.79.

The security has been trending lower on the charts since its Aug. 17, all-time high of $275.87. Shares have also slipped below support at the 40-day moving average, which was instrumental in the stock's climb, though the $230 area could capture this recent pullback. Longer term, Eli Lilly stock still sports a healthy 51.2% year-over-year lead.

Analysts are bullish towards LLY. Of the 11 in question, nine carry a "strong buy" rating, while two say "hold." Plus, the stock's 12-month consensus target price of $265.88 is a 15.5% premium to current levels.

The options pits are not as optimistic. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), LLY's 50-day put/call volume ratio is higher than 91% of readings from the last 12 months. This means long puts have been getting picked up at a much quicker-than-usual clip.

Echoing this, the stock's Schaeffer's put/call open interest ratio (SOIR) of 1.40 stands in the 95th annual percentile, suggesting short-term options traders have rarely been more put-biased. 

It is worth noting LLY ranks high on the Schaeffer's Volatility Scorecard (SVS), with a score of 91 out of 100. This suggests the stock has consistently realized higher volatility than the options pits have priced in, making it a solid premium-buying candidate.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners